<DOC>
	<DOCNO>NCT00008333</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . PURPOSE : Phase II trial study effectiveness vinorelbine take mouth treat old patient stage IIIB stage IV non-small cell lung cancer .</brief_summary>
	<brief_title>Vinorelbine Treating Older Patients With Stage IIIB Stage IV Non-small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine objective response rate elderly patient stage IIIB IV non-small cell lung cancer treat oral vinorelbine . II . Determine time progression patient treat drug . III . Determine toxicity drug patient . IV . Determine whether perceive preference oral administration patient . V. Determine quality life patient treated drug . VI . Assess individual variation response , pharmacokinetic parameter , and/or biological correlate patient treated drug . OUTLINE : Patients receive oral vinorelbine day 1 , 8 , 15 , 22 . Treatment repeat every 28 day 4-6 course absence disease progression unacceptable toxicity . Quality life assess baseline 8 week therapy . Patients follow every 3 month 5 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage IIIB IV nonsmall cell lung cancer Measurable disease At least 1 lesion 2.0 cm long diameter CNS metastases allow previously treat clinically stable least 8 week prior study No meningeal carcinomatosis Participation translational research component study mandatory PATIENT CHARACTERISTICS : Age : 65 Performance status : ECOG 02 Life expectancy : At least 12 week Hematopoietic : Platelet count least 100,000/mm3 Hemoglobin least 10.0 g/dL Absolute neutrophil count least 1,500/mm3 Hepatic : Bilirubin great 2.0 mg/dL Renal : Creatinine great 2 time upper limit normal Other : No dysphagia inability swallow capsule intact No peripheral neuropathy grade 2 great No significant medical condition would preclude study No active infection within past 2 week No malignancy within past 5 year PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy disease within past 5 year Endocrine therapy : Not specify Radiotherapy : At least 3 week since prior radiotherapy recover No prior radiotherapy 25 % bone marrow No prior radiotherapy measurable lesion unless document progression therapy No concurrent radiotherapy , include palliative radiotherapy Surgery : At least 3 week since prior major surgery</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
</DOC>